EC Healthcare : appoints Chief Operating Officer, Chief Public Affairs Officer & Chief Dental Officer and Chief Talent Officer Further Expansion in Senior Management Team Empowering the Group to Achieve High Quality Growth







[FOR IMMEDIATE RELEASE]

EC Healthcare appoints Chief Operating Officer, Chief Public Affairs Officer

& Chief Dental Officer and Chief Talent Officer

Further Expansion in Senior Management Team Empowering the Group to

Achieve High Quality Growth

(27 July 2022, Hong Kong) EC Healthcare (the “Company”, which together with its subsidiaries is referred to as the “Group”, SEHK stock code: 2138), the largest non-hospital medical group in Hong Kong*, is pleased to announce that the Group further expanded its CXO platform, appoint Mr. Andrew Wong as Chief Operating Officer, Dr. Eugene Chan (SBS, BBS, JP) as Chief Public Affairs Officer & Chief Dental Officer and Mr. CY Chan as Chief Talent Officer.

Mr. Andrew Wong joined the Group as Chief Operating Officer, responsible for establishing the operational protocol, overseeing the day-to-day operations and drive the improvement of operational efficiency and services quality. Mr. Wong owns substantial experience of over 20 years in the banking and finance industry. Mr. Wong acquired a Master’s Degree of Business Administration at Harvard Business School and a Bachelor’s Degree of Business Administration (Accounting and Finance) at The University of Hong Kong. Prior to joining the Group, Mr. Wong had been the Chief Executive Officer and Executive Director at Clarity Medical Group (SEHK: 1406.HK) and was the Chief Financial Officer and Executive Director of many listing companies of energy sector. Mr. Wong also accumulates extensive experiences during his employment at BNP Paribas (Hong Kong), Royal Bank of Scotland, Merrill Lynch, and Citi.

Dr. Eugene Chan appointed by the Group as Chief Public Affairs Officer & Chief Dental Officer, responsible for the Group’s public affairs to oversee the Group’s medical practice in line with the government’s guidance. He is also responsible for the Group’s overall dental business operation. Dr. Chan has practiced for more than 30 years in the medical industry, and he provides consultation services to advisory and statutory bodies. Dr. Chan acquired a bachelor’s degree of Dental Surgery at the University of Adelaide, attained the Memberships of Faculty of General Dental Practice (UK) [MFGDP(UK)], Membership of General Dental Dentistry of the Hong Kong College of Dental Surgeons [MGD(CDSHK)], plus, was conferred the Faculty of General Dental Practitioners (UK) and Diploma in Implant Dentistry (Dip. Imp. Dent RCS Eng) as well as the Advance Certificate in Implant Dentistry of Royal College of Surgeons of England. Dr. Chan is now an Honorary Clinical Associate Professor of the Chinese University of Hong Kong, a Visiting Professor of the Jinan University in the People’s Republic of China, as well as the Chairman of The Outstanding Young Persons’ Association and the Association of Hong Kong Professionals. In addition, he has also taken multiple positions in Hong Kong and overseas Professional Dental Committees. Dr. Chan has been actively engaged in public affairs, he is a current Council Member of City University of Hong Kong, a member of the Advisory Committee of School of Chinese Medicine of Hong Kong Baptist University, a member of Action Committee Against Narcotics, a member of Fight Crime Committee, and the anchor host of weekly English current affairs programme Straight Talk. Dr. Chan was selected as an awardee of the Ten Outstanding Young Persons and appointed by the Government of the Hong Kong Special Administrative Region as a Justice of the Peace

EC Healthcare appoint Chief Operating Officer, Chief Public Affairs Officer and Chief Dental Officer and Chief Talent Officer 27 July 2022, Page 2

and was awarded a Bronze Bauhinia Star and Silver Bauhinia Star soon after, as a recognition of his eminent accomplishments.

Mr. CY Chan joined the Group as Chief Talent Officer, responsible for overseeing the talent and culture strategy and operations to drive the Group forward via long-term talent engagement, management, and employment branding. Mr. Chan has over 10 years of professional experiences in talent acquisition, engagement & development, and administration. He graduated from Hong Kong Baptist University with a Master degree in Strategic Human Resources Management and City University of Hong Kong with a Master degree in Applied Psychology. Mr. Chan is also an alumnus of the Stanford Executive Program from Stanford Graduate School of Business. Prior to joining the Group, Mr. Chan had been the Chief People Officer of Prenetics Global Limited (NASDAQ: PRE) and the Chief Talent & Purpose Officer of Hong Kong Broadband Group (SEHK: 1310.HK). Mr. Chan’s career journey features a variety of key roles in talent management, sales, consulting, and corporate social investment, across different industries.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, “The Group sincerely welcomes top talents to join the Group and further expand our CXO team. With their leadership, the Group shall be able to achieve high-qualitygrowth. The Group has always attached great emphasis on building a platform for all talent. We wish to share best practices systematically to help every talent in the Group to maximize their personal value and achieve career success. CXO platform is a crucial part of our talent strategy, the experience of outstanding talents empowers the Group to consolidate the leading market position and lead industry revolution. Looking forward, we have great confidence in the Group’s growth. The Group will continue to consolidate the healthcare market and make unremitting efforts to be the Asia leading healthcare platform.”

– End –

About EC Healthcare

EC Healthcare is Hong Kong’s largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group’s high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, primary care clinics jointly established with Tencent Doctorwork, chiropractic services centre New York Spine and Physiotherapy Center NYMG, health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, a comprehensive dental centre UMH DENTAL CARE, a diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic SPECIALISTS CENTRAL, NEW MEDICAL CENTER and Prime Medical Centres, obstetrics and gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, specialists central, a paediatric center PRIME CARE, cardiology center HONG KONG INTERNATIONAL CARDIOLOGY CENTER, PathLab Medical Laboratories, a professional hair care center HAIR FOREST, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021

Disclaimer

EC Healthcare published this content on 27 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 July 2022 08:21:07 UTC.

Publicnow 2022

All news about EC HEALTHCARE

Sales 2022 2 869 M
366 M
304 M
Net income 2022 349 M
44,4 M
36,9 M
Net cash 2022 778 M
99,1 M
82,4 M
P/E ratio 2022 23,7x
Yield 2022 2,79%
Capitalization 8 343 M
1 063 M
884 M
EV / Sales 2022 2,64x
EV / Sales 2023 2,16x
Nbr of Employees 2 674
Free-Float 35,7%



Duration :


Period :




EC Healthcare Technical Analysis Chart | MarketScreener

Technical analysis trends EC HEALTHCARE

Short Term Mid-Term Long Term
Trends Neutral Neutral Bearish

Income Statement Evolution

Sell

Buy

Mean consensus BUY
Number of Analysts 7
Last Close Price 7,15 HKD
Average target price 11,53 HKD
Spread / Average Target 61,3%


Source

Similar Posts